Interim Report January – June 2022
Copenhagen, Denmark, 25 August 2022 - Curasight A/S ("Curasight" or the “Company" - TICKER: CURAS) hereby publishes the interim report for the period January 1 – June 30, 2022. The interim report is available as an attached file to this release and on the Company’s website. Below is a summary of the report.
Curasight’s CEO Ulrich Krasilnikoff comments:
“During the first half of 2022, we have actively worked on strengthening key values to accelerate Curasight’s position as a theranostic company. I am thinking in particular of our recently expanded strategy, the granting of our US patent application relating to uTRACE© and the successful recruitment of the remaining patients to the investigator-initiated phase II study (uTRACE©) in brain cancer. Every day we continue to advance Curasight’s technology, and I am convinced that we are on the right path toward our mission – to improve the lives of millions of people suffering from cancer.”
Q2 (April – June) 2022
- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -1,919,541 (-404,869) DKK
- Profit/loss before taxes amounted to -2,876,062 (-1,079,213) DKK
- Profit/loss for the period amounted to -2,243,328 (-841,783) DKK
- Total assets amounted to 99,297,297 (60,860,495) DKK
- Equity ratio amounted to 96,3 (94,4) %.
- Earnings per share amounted to -0,11 (-0,05) DKK
H1 (January – June) 2022
- Net sales amounted to 0 (0) DKK
- Operating profit/loss amounted to -2,697,418 (-771,962) DKK
- Profit/loss before taxes amounted to -4,492,362 (-2,076,728) DKK
- Profit/loss for the period amounted to -3,504,042 (-1,619,848) DKK
- Total assets amounted to 99,297,297 (60,860,495) DKK
- Equity ratio amounted to 96,3 (94,4) %.
- Earnings per share amounted to -0,17 (-0,09) DKK
Highlights during the first quarter
- On April 22, Curasight announced that the United States Patent and Trademark Office has granted Curasight’s United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137.
- On April 25, Ulrich Krasilnikoff and Andreas Kjær were invited and attended Sedermeradagen Stockholm. The presentation is available on Sedermeras Youtube channel.
- On April 27, Curasight held an Annual General Meeting. Resolutions with summarized decisions are available on the company’s website.
- On May 18, Ulrich Krasilnikoff and Andreas Kjær gave an update on the company’s strategy at Kapital Partner’s Life Science Seminar.
- On June 7, Curasight issued a total of 956,770 warrants for the purpose of launching the Company’s long-term incentive program covering the Company’s Board of Directors, Executive Management and other key employees.
- On June 24, Curasight announced that a transaction with shares in Curasight A/S was made by managerial employee in the period 9 – 10 June 2022. Hanne Damgaard Jensen (Chief Development Officer) bought a total of 16.400 shares. Hanne Damgaard Jensen total holdings in Curasight A/S after the purchase of the shares is 20,000 shares.
- On June 30, Curasight announced that the investigator-initiated phase II study using uPAR-PET in brain cancer had completed the inclusion of patients. First data from the study is expected to be published during H2 2022.
Highlights after the period
- No other significant events have occurred since the end of the period that has materially affected this report.
For more information regarding Curasight, please contact:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology provides improved diagnosis and risk stratification in multiple cancer types.